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Dear Editors 
Abnormalities of neurotransmission via dopamine and glutamine in the brain 
have long been thought to be involved in the pathophysiology of schizophrenia (Howes 
and Kapur, 2009; Moghaddam and Javitt, 2012). In addition, involvement of even more 
factors such as D-serine, an allosteric modulator of N-methyl-D-aspartate (NMDA) 
receptor, γ-aminobutyric acid (GABA) and abnormal immune system have been 
independently proposed (Chiapponi et al., 2016; Jones et al., 2005; Nunes et al., 2012). 
These factors may contribute to the pathophysiology of schizophrenia interdependently. 
Hippocampus is one of the brain regions that shows significant alteration in 
schizophrenia, such as volume change (Heckers and Konradi, 2002). Kraguljac et al. 
reported increased level of glutamate in unmedicated patients with schizophrenia by using 
magnetic resonance imaging (Kraguljac et al., 2013). Although altered levels of other 
neurotransmitters have been assumed, it is difficult to measure each neurotransmitter with 
high specificity and sensitivity.  
Recently, a combination of liquid chromatography and mass spectrometry 
(LCMS) has enabled highly sensitive and high-throughput measurement of biological 
compounds. Especially, Multiple-Reaction Monitoring (MRM) is particularly sensitive 
and selective method for measuring small molecules. Using the MRM method, we herein 
measured various neurotransmitters at the same time in the hippocampus of cuprizone-
treated mice, which is relevant for schizophrenia-related abnormalities (Xiao et al., 2008; 
Zhang et al., 2008), and we also evaluated the effect of quetiapine, a widely-used 
antipsychotic drug. 
 
A detailed description of our method is shown in the supplemental materials. 
Briefly, C57BL/6 mice (male, 8 weeks old) were randomly allocated to four groups (CT, 
Control; CP, Cuprizone; CP+ VH, Cuprizone and, Vehicle; and CP+QP, Cuprizone and 
Quetiapine). For one week, mice were fed either a diet containing 0.2% cuprizone, or a 
control diet consisting standard mouse chow. Saline (VH group) or quetiapine (10 mg/kg, 
QP group) were administrated intraperitoneally 1, 2, 3, and 4 days prior to the experiment. 
The whole brain from each mouse was removed and each left part of brain was heat-
stabilized to inactivate the enzymes. Hippocampus was carefully isolated from the heated 
brain tissue. The extracts of the homogenized hippocampi were used for MRM analysis. 
MRM data were processed to acquire peak area of target compounds and the signal levels 
were normalized to the internal standard (4-hydroxybenzophenone). 
 
To examine the effect of cuprizone exposure on neurotransmitters in 
hippocampus, we measured 20 compounds by means of MRM using a triple quadrupole 
mass spectrometer. The majority of compounds did not show significant change in their 
intensity level (Bonferroni-corrected significance level: 0.05/20 = 2.5E-3). On the other 
hand, drastic changes were observed in serine, GABA and glycine (Fig 1ABC). The 
signal level of Serine in cuprizone-exposed group showed a 75 % decrease. GABA level 
showed a remarkable increase of 300 %. 
Further, we examined the effect of quetiapine on these three compounds in cuprizone-
treatment mice (Fig. 1DEF). The signal level of serine and GABA were significantly 
rescued by quetiapine treatment (Fig. 1DE). However, the signal level of glycine was not 
rescued by quetiapine treatment (Fig. 2F). 
 
Glutamine hypothesis is one of the major models for the pathologic mechanism 
to explain schizophrenia, and a number of reports support the theory (Coyle, 1996; 
Moghaddam and Javitt, 2012). We performed systematic analysis of the effect of 
cuprizone on the neurotransmitters in hippocampus, however we could not detect 
significant change in the level of difference in glutamine, glutamic acid and 
glutamine/glutamic acid ratio. On the other hand, serine, glycine and GABA showed 
prominent changes in their signal levels in cuprizone-treated mice, both of which have 
been thought to be involved in the pathophysiology of schizophrenia (Tuominen et al., 
2005). D-serine works as a neurotransmitter involved in glia-synapse interaction and D-
serine diminishes NMDA neurotransmission. In addition, plasma serine levels were 
reported to be decreased in patients with schizophrenia (Sumiyoshi et al., 2004). Glycine 
is an obligatory co-agonist of NMDA receptors, and NMDA receptor-mediated 
glutamatergic neurotransmission is suggested to be one of the main causes of 
schizophrenia (Labrie and Roder, 2010). Decreased level of GABA in hippocampus and 
other brain regions in patients with schizophrenia has been reported (Heckers and Konradi, 
2015; Steiner et al., 2016) . However, we observed increased level of GABA in the 
hippocampus of cuprizone-treated mice. In this study, we analyzed tissue extract, 
therefore the GABA level does not necessarily reflect the amount of GABA in the 
synaptic junction. Further investigations are required to illustrate the roles of GABA 
under the pathophysiology of schizophrenia. 
Quetiapine is one of the major atypical antipsychotics used for schizophrenia, 
bipolar disorder and major depression (Riedel et al., 2007). The present result has 
suggested that quetiapine alleviate clinical symptoms by modulating the level of serine 
and GABA in hippocampus. It is still unknown how quetiapine affects the synthesis or 
metabolism of serine and GABA in hippocampus. One-week treatment of cuprizone is 
known to activate glial cells including astrocytes and microglia before demyelination 
(Tezuka et al., 2013). On the other hand, microglial activation has been highlighted in 
schizophrenia including at high-risk stage (Bloomfield et al., 2016; Monji et al., 2009; 
Selvaraj et al., 2018). We previously reported that various antipsychotics including 
quetiapine have an effect to down-regulate the activation of microglia in vitro (Bian et al., 
2008; Kato et al., 2007; Kato et al., 2011; Sato-Kasai et al., 2016; Seki et al., 2013), and 
in vivo studies have shown suppressing effects of quetiapine in cuprizone treatment model 
(Shao et al., 2015; Wang et al., 2015; Xiao et al., 2008; Zhang et al., 2008; Zhang et al., 
2012). Thus, microglia modulating effects of quetiapine may be one of the possible 
underlying mechanisms in the present result. Other molecular mechanisms should also be 
considered using different schizophrenia-related models (Kraeuter et al., 2019).  
Based on this study, we have proposed that cuprizone-treated mice may be an 
appropriate model showing the abnormalities of GABA, serine and glycine in the 
pathology of schizophrenia, but not suitable to examine the glutamine abnormalities of 
schizophrenia. Further translational studies including behavioral experiments are needed 
to understand the multi-factorial mechanisms of schizophrenia using the present model 
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Fig. 1. Effects of cuprizone and quetiapine on serine, GABA and glycine. Data points of 
MRM signal of each samples, mean value and standard deviation are indicated (N = 8). 
CT, control; CP, cuprizone; VH, vehicle; QP, quetiapine. Statistical analysis was 
performed using the unpaired Student’s t-test. A p-value <0.05 was considered 
statistically significant. We applied a conservative Bonferroni correction to control for 
false-positive deriving from multiple testing. P values ≤ 0.05 / (number of metabolites 
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